Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays-Reference-Cited by-同舟云学术

Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

Published:2024-06-24 Issue:2 Volume:130 Page:166-187
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:Journal of Surgical Oncology

Author:

Hyams David M.¹^ORCID,Bareket‐Samish Avital²,Rocha Juan Enrique Bargallo³,Diaz‐Botero Sebastian⁴,Franco Sandra⁵,Gagliato Debora⁶,Gomez Henry L.⁷,Korbenfeld Ernesto⁸,Krygier Gabriel⁹,Mattar Andre¹⁰,De Pierro Aníbal Nuñez¹¹,Borrego Manuel Ruiz¹²,Villarreal Cynthia¹³

Affiliation:

1. Medical Director Desert Surgical Oncology, Eisenhower Medical Center Rancho Mirage California USA

2. BioInsight Ltd. Binyamina Israel

3. Breast Cancer Department Instituto Nacional de Cancerología Mexico and Centro Medico ABC Mexico City Mexico

4. Breast Surgical Oncology Unit Cancer Center at Clínica Universidad de Navarra Madrid Spain

5. Medical Director Centro de Tratamiento e Investigación sobre el Cáncer, CTIC Bogotá Colombia

6. Department of Clinical Oncology Beneficencia Portuguesa de Sao Paulo San Paulo Brazil

7. Breast Unit Director OncoSalud, Clinica Delgado, AUNA, Universidad Ricardo Palma, Universidad Peruana Cayetano Heredia Lima Peru

8. Department of Oncology Hospital Británico de Buenos Aires Buenos Aires Argentina

9. Department of Oncology Universitary Hospital de Clínicas Montevideo Uruguay

10. Director of Mastology Center Centro de Referência da Saúde da Mulher, Hospital da Mulher São Paulo Brazil

11. Department of Surgery Unit of Mastology, Hospital J.A. Fernandez Buenos Aires City Argentina

12. Medical Oncology Service Hospital Universitario Virgen del Rocío Seville Spain

13. Head, Department of Medical Oncology, Breast Cancer Center Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey Monterrey Nuevo Leon Mexico

Abstract

AbstractGene expression assays (GEAs) can guide treatment for early‐stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.27692

Reference140 articles.

1. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

2. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

3. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

4. Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

5. A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors